Drug intelligence / Profile preview

VXN-LEISH

Development stage: Preclinical
Lead developer: Vaxinano
Modality: Vaccines & Immunotherapeutics
Administration: Mucosal

Overview

**VXN-LEISH** is a investigational vaccine candidate developed by Vaxinano for the prevention of canine leishmaniasis, a zoonotic disease caused by *Leishmania* parasites transmitted by sandflies. It utilizes Vaxinano's versatile mucosal vaccine platform, designed for prophylactic or therapeutic use against zoonoses including leishmaniasis. The vaccine entered an exclusive licensing agreement with Vetoquinol in 2024, enabling commercialization for canine applications within three years of development. Its mechanism likely involves mucosal immunity induction to block parasite transmission in dogs, a key reservoir host, though specific antigens and adjuvants remain undisclosed in public sources.

Beyond the preview

Go deeper on VXN-LEISH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VXN-LEISH.

Explore the full profile